Drug therapy to reduce early readmission riskin heart failure: Ready for prime time?

Muthiah Vaduganathan; Gregg C. Fonarow; Mihai Gheorghiade

doi:10.1016/j.jchf.2013.04.010

Drug therapy to reduce early readmission riskin heart failure: Ready for prime time?

Muthiah Vaduganathan, Gregg C. Fonarow, Mihai Gheorghiade^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Readmission for heart failure remains a major focus of policymakers, clinicians, and patients. Despite meeting key national performance measures and frequent use of evidence-based therapies, rates of 30-day post-discharge rehospitalization may be as high as 25%. Digoxin and mineralocorticoid antagonists are known to reduce admissions for heart failure, but are significantly underused in current clinical practice despite their proven benefits.

Original language	English (US)
Pages (from-to)	361-364
Number of pages	4
Journal	JACC: Heart Failure
Volume	1
Issue number	4
DOIs	https://doi.org/10.1016/j.jchf.2013.04.010
State	Published - Aug 2013

Keywords

ACE
ARB
Acute heart failure
Digoxin
EF
HF
MRA
Mineralocorticoid receptor antagonists
Readmissions

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jchf.2013.04.010

Cite this

@article{748d900cb55b4b049b7bdb5fc1c3bffb,

title = "Drug therapy to reduce early readmission riskin heart failure: Ready for prime time?",

abstract = "Readmission for heart failure remains a major focus of policymakers, clinicians, and patients. Despite meeting key national performance measures and frequent use of evidence-based therapies, rates of 30-day post-discharge rehospitalization may be as high as 25%. Digoxin and mineralocorticoid antagonists are known to reduce admissions for heart failure, but are significantly underused in current clinical practice despite their proven benefits.",

keywords = "ACE, ARB, Acute heart failure, Digoxin, EF, HF, MRA, Mineralocorticoid receptor antagonists, Readmissions",

author = "Muthiah Vaduganathan and Fonarow, {Gregg C.} and Mihai Gheorghiade",

year = "2013",

month = aug,

doi = "10.1016/j.jchf.2013.04.010",

language = "English (US)",

volume = "1",

pages = "361--364",

journal = "JACC: Heart Failure",

issn = "2213-1779",

publisher = "Elsevier BV",

number = "4",

}

TY - JOUR

T1 - Drug therapy to reduce early readmission riskin heart failure

T2 - Ready for prime time?

AU - Vaduganathan, Muthiah

AU - Fonarow, Gregg C.

AU - Gheorghiade, Mihai

PY - 2013/8

Y1 - 2013/8

N2 - Readmission for heart failure remains a major focus of policymakers, clinicians, and patients. Despite meeting key national performance measures and frequent use of evidence-based therapies, rates of 30-day post-discharge rehospitalization may be as high as 25%. Digoxin and mineralocorticoid antagonists are known to reduce admissions for heart failure, but are significantly underused in current clinical practice despite their proven benefits.

AB - Readmission for heart failure remains a major focus of policymakers, clinicians, and patients. Despite meeting key national performance measures and frequent use of evidence-based therapies, rates of 30-day post-discharge rehospitalization may be as high as 25%. Digoxin and mineralocorticoid antagonists are known to reduce admissions for heart failure, but are significantly underused in current clinical practice despite their proven benefits.

KW - ACE

KW - ARB

KW - Acute heart failure

KW - Digoxin

KW - EF

KW - HF

KW - MRA

KW - Mineralocorticoid receptor antagonists

KW - Readmissions

UR - http://www.scopus.com/inward/record.url?scp=84881528217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881528217&partnerID=8YFLogxK

U2 - 10.1016/j.jchf.2013.04.010

DO - 10.1016/j.jchf.2013.04.010

M3 - Review article

C2 - 24621940

AN - SCOPUS:84881528217

SN - 2213-1779

VL - 1

SP - 361

EP - 364

JO - JACC: Heart Failure

JF - JACC: Heart Failure

IS - 4

ER -

Drug therapy to reduce early readmission riskin heart failure: Ready for prime time?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this